These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31653527)

  • 41. Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data.
    Diaz J; Terrazas S; Bierrenbach AL; Toscano CM; Alencar GP; Alvarez A; Valenzuela MT; Andrus J; del Aguila R; Hormazábal JC; Araya P; Pidal P; Matus CR; de Oliveira LH
    PLoS One; 2016; 11(4):e0153141. PubMed ID: 27058873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective, population-based surveillance of the burden of Streptococcus pneumoniae in community-acquired pneumonia in older adults, Chrzanów County, Poland, 2010 to 2012.
    Harat R; Alexander R; Gray S; Gutterman EM; Pluta J; Pride M; Shite S; Fijolek J; Kozub J
    Pneumonol Alergol Pol; 2016; 84(2):95-103. PubMed ID: 27238167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
    López EL; Glatstein E; Ezcurra GC; Iacono M; Teplitz E; Garnero AV; Lazzarini DL; Vázquez M; Contrini MM
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):30-35. PubMed ID: 28339727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules.
    Lee HY; Hsieh YC; Liu CC; Huang YC; Chang KY; Chi H; Chang LY; Huang YC; Huang LM;
    J Microbiol Immunol Infect; 2018 Apr; 51(2):199-206. PubMed ID: 29021105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine?
    McIntosh ED
    Arch Dis Child; 2003 Oct; 88(10):859-61. PubMed ID: 14500302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance.
    Sgambatti S; Minamisava R; Bierrenbach AL; Toscano CM; Vieira MA; Policena G; Andrade AL
    Vaccine; 2016 Jan; 34(5):663-670. PubMed ID: 26706272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pneumonia hospitalizations and mortality in children 3 - 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10).
    Iliya J; Shatima DR; Tagbo BN; Ayede AI; Fagbohun AO; Rasaq A; Nalban S; Elon IW; Mohammed-Nafiu R; Ahmed P; Oyewole OB; Bakare AA; Yusuf BO; Akinrinoye OO; Ogala WN; Falade AG
    Hum Vaccin Immunother; 2023 Dec; 19(1):2162289. PubMed ID: 36597576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Macgregor V; Trotter C; Slack M; George R; Lim WS
    Thorax; 2014 Feb; 69(2):168-73. PubMed ID: 24048505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013.
    López-de-Andrés A; de Miguel-Díez J; Jiménez-Trujillo I; Hernández-Barrera V; de Miguel-Yanes JM; Méndez-Bailón M; Pérez-Farinós N; Salinero-Fort MÁ; Jiménez-García R
    BMJ Open; 2017 Jan; 7(1):e013097. PubMed ID: 28057653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
    van Werkhoven CH
    Hum Vaccin Immunother; 2017 May; 13(5):1177-1181. PubMed ID: 27937061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.
    Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA
    Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation.
    Demirdogen Cetinoglu E; Uzaslan E; Sayıner A; Cilli A; Kılınc O; Sakar Coskun A; Hazar A; Kokturk N; Filiz A; Polatli M;
    Hum Vaccin Immunother; 2017 Sep; 13(9):2072-2077. PubMed ID: 28708954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
    Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
    Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
    Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
    Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001-2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain).
    España PP; Uranga A; Ruiz LA; Quintana JM; Bilbao A; Aramburu A; Serrano L; Ayarza R; Martinez AP; Zalacain R
    Vaccine; 2019 Jun; 37(29):3840-3848. PubMed ID: 31153692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
    Ioachimescu OC; Ioachimescu AG; Iannini PB
    Int J Antimicrob Agents; 2004 Nov; 24(5):485-90. PubMed ID: 15519482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands.
    Vestjens SMT; Wagenvoort GHJ; Grutters JC; Meek B; Aldenkamp AF; Vlaminckx BJM; Bos WJW; Rijkers GT; van de Garde EMW
    Vaccine; 2017 Jul; 35(33):4112-4118. PubMed ID: 28668570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.